@article{3220377,
    title = "Sub-population analysis of patients with plaque psoriasis treated with calcipotriol/betamethasone aerosol foam; effectiveness and patient satisfaction, according to baseline disease severity and prior psoriasis treatment experience, in a Greek population",
    author = "Rigopoulos, D. and Lazaridou, E. and Papadavid, E. and Georgiou, S. and Chasapi, V. and Sfaelos, K. and Cheliotis, G. and Ioannides, D.",
    journal = "Dermatologic Therapy",
    year = "2022",
    volume = "35",
    number = "6",
    publisher = "John Wiley and Sons Inc",
    issn = "1396-0296, 1529-8019",
    doi = "10.1111/dth.15484",
    keywords = "betamethasone;  calcipotriol;  calcitriol;  dermatological agent;  prostaglandin A, aerosol;  complication;  drug combination;  Greece;  human;  patient satisfaction;  psoriasis;  severity of illness index;  treatment outcome, Aerosols;  Betamethasone;  Calcitriol;  Dermatologic Agents;  Drug Combinations;  Greece;  Humans;  Patient Satisfaction;  Prostaglandins A;  Psoriasis;  Severity of Illness Index;  Treatment Outcome",
    abstract = "Fixed combination calcipotriol/betamethasone (Cal/BD) aerosol foam has been shown to be effective in psoriasis treatment in clinical trials, but real-world evidence is currently sparse. The real-world CELSUS study in Greece found that Cal/BD aerosol foam treatment was effective and associated with satisfaction in psoriasis patients. Patients from the CELSUS study (N = 400) were stratified by baseline disease severity according to physician's global assessment (PGA) score (mild vs. moderate vs. severe) and by previous psoriasis treatment (naïve vs. treatment-experienced). Proportions of patients achieving treatment success (clear/almost clear [PGA 0/1]) after 4 weeks' treatment with Cal/BD aerosol foam were reported for each subgroup. Psoriasis area and severity index (PASI) and patient-reported itch, itch-related sleep loss, scaling, dry skin, and erythema numerical rating scores were reported by subgroup. At baseline, 216 (54%) patients were systemic-or-topical psoriasis treatment-naïve and 184 (46%) were treatment experienced. By disease severity, there were 135 versus 89 patients with mild, 69 versus 83 with moderate and 12 versus 12 with severe disease in the treatment-naïve versus treatment-experienced groups, respectively. In the treatment-naïve group, treatment success was achieved by 72.6%, 56.5%, and 66.7% of patients with mild, moderate, and severe disease, respectively, while the proportions in the treatment-experienced group were 60.7%, 42.2%, and 25%, respectively. Reduction from baseline in psoriasis symptoms was observed in all patient groups. The greatest reductions were observed in treatment-naïve patients with severe disease. Clinically relevant benefits were observed with Cal/BD aerosol foam in psoriasis patients, regardless of prior treatment-experience and disease severity at baseline. © 2022 Wiley Periodicals LLC."
}